Apply to trial NCT07228221

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 4Device study

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening